2.50
Hdl Handle:
http://hdl.handle.net/10541/83568
Title:
The clinical development of the bryostatins.
Authors:
Clamp, Andrew R; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. aclamp@picr.man.ac.uk
Citation:
The clinical development of the bryostatins. 2002, 13 (7):673-83 Anticancer Drugs
Journal:
Anticancer Drugs
Issue Date:
Aug-2002
URI:
http://hdl.handle.net/10541/83568
PubMed ID:
12187323
Type:
Article
Language:
en
ISSN:
0959-4973
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorClamp, Andrew Ren
dc.contributor.authorJayson, Gordon Cen
dc.date.accessioned2009-10-05T15:08:21Z-
dc.date.available2009-10-05T15:08:21Z-
dc.date.issued2002-08-
dc.identifier.citationThe clinical development of the bryostatins. 2002, 13 (7):673-83 Anticancer Drugsen
dc.identifier.issn0959-4973-
dc.identifier.pmid12187323-
dc.identifier.urihttp://hdl.handle.net/10541/83568-
dc.description.abstractThe bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBryostatins-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshClinical Trials, Phase I as Topic-
dc.subject.meshClinical Trials, Phase II as Topic-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy, Adoptive-
dc.subject.meshLactones-
dc.subject.meshMacrolides-
dc.subject.meshNeoplasms-
dc.titleThe clinical development of the bryostatins.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. aclamp@picr.man.ac.uken
dc.identifier.journalAnticancer Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.